Beyond convenience : does subcutaneous pembrolizumab add value for patients and health systems?
Source
Journal of clinical oncology - ISSN 0732-183X-44:20 (2026) p. 1860-1864
RECITE this mantra in chemotherapy-induced thrombocytopenia : treat patients, not platelets
Source
Nature Reviews Clinical Oncology - ISSN 1759-4774-23:8 (2026) p. 562-563
Inferior control arms in oncology trials in LMICs : contextualised or compromised?
Source
BMJ oncology - ISSN 2752-7948-4:1 (2025) p. 1-2
Overall survival assessment in cancer drug trials : a luxury or a necessity?
Source
The lancet oncology - ISSN 1470-2045-26:11 (2025) p. 1402-1404
Assessing clinical value of new treatment strategies : ESMO-MCBS and ASCO-VF evaluation in phase III trials at ASCO Annual Meeting 2022
Source
JCO oncology practice - ISSN 2688-1527-21:9 (2025) p. 1-11